Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lung cancer].

Masahiro Tsuboi1, Harubumi Kato

  • 1Dept. of General Thoracic Surgery, Tokyo Medical University, Nishi-shinjyuku, Tokyo, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 18, 2007
PubMed
Summary
This summary is machine-generated.

Neoadjuvant chemotherapy offers a modest survival benefit for early-stage non-small cell lung cancer (NSCLC). However, current evidence suggests this approach remains investigational and should be confined to clinical trials.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient and hospital factors for outcomes of completely resected, node-negative nonsmall cell lung cancer.

Japanese journal of clinical oncology·2025
Same author

CRES<sup>3</sup>T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumors.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.

Nature medicine·2025
Same author

Solid Predominant Histology and High Podoplanin Expression in Cancer-Associated Fibroblast Predict Primary Resistance to Osimertinib in <i>EGFR</i>-Mutated Lung Adenocarcinoma.

JTO clinical and research reports·2025
Same author

Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Potential of spectral imaging generated by contrast-enhanced dual-energy CT for lung cancer histopathological classification - A preliminary study.

European journal of radiology open·2025
Same journal

[A Case of Pulmonary Epithelioid Hemangioendothelioma Associated with Multiple Cancers].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Long-Term Survival in Three Cases with Pulmonary Metastases from Colorectal Cancer Given Low-Dose S-1 Under a Regimen Combining a Carbohydrate-Restricted Ketogenic Diet, Metformin, Vitamin D, Eicosapentaenoic Acid, and Other Complementary Therapies].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Preventive Effect of Saline Eye Wash for Eye Symptoms Due to High-Dose and Intermediate-Dose Cytarabine Therapy].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Examination of Factors Affecting the Efficacy of Naldemedine Tosilate Tablets for Opioid-Induced Constipation].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[Recent Advances in the Treatment of HER2-Altered Solid Tumors].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
Same journal

[BRAF-Mutant Solid Tumor].

Gan to kagaku ryoho. Cancer & chemotherapy·2026
See all related articles

Area of Science:

  • Oncology
  • Thoracic Surgery
  • Medical Oncology

Context:

  • Surgery is the primary curative treatment for early-stage non-small cell lung cancer (NSCLC).
  • Despite surgical intervention, modest 5-year survival rates necessitate improved therapeutic strategies.
  • Neoadjuvant chemotherapy has been explored to enhance outcomes in resectable NSCLC.

Purpose:

  • To evaluate the efficacy of neoadjuvant chemotherapy in improving survival rates for early-stage non-small cell lung cancer.
  • To synthesize evidence from randomized trials and meta-analyses regarding neoadjuvant chemotherapy's impact on NSCLC survival.

Summary:

  • While early trials suggested benefits, subsequent randomized trials have not shown statistically significant improvements in overall survival with neoadjuvant chemotherapy for NSCLC.

Related Experiment Videos

  • A meta-analysis of 8 trials indicated a 12% relative benefit (HR 0.88) with neoadjuvant chemotherapy, translating to a 5% absolute 5-year survival improvement.
  • For stage N2-III A NSCLC, a US intergroup trial found no significant difference in overall survival between surgery with or without neoadjuvant chemoradiotherapy.

    • Impact:

    • Current scientific evidence does not support the routine use of neoadjuvant chemotherapy for early-stage NSCLC in clinical practice.
    • The neoadjuvant strategy for NSCLC is considered investigational and should be limited to the context of clinical trials.
    • Further research is required to establish the definitive role and optimal application of neoadjuvant therapies in NSCLC management.